| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 3, 2026
Following recent U.S. Food and Drug Administration (FDA) labeling approval, European label milestone reinforces Medtronic leadership in advancing aortic care based on clinical evidence supporting the treatment of ruptured abdominal aortic aneurysms (rAAA).
-
Jul 1, 2025
Medtronic expands its cardiac surgical and respiratory innovation portfolio with the launch of the VitalFlow ECMO System
-
May 6, 2024
Symplicity Spyral is the first renal denervation technology to be approved by the National Medical Products Administration; new, innovative, minimally invasive procedure uses radiofrequency energy to help reduce high blood pressure
-
Mar 19, 2024
Medtronic today announced it received a license from Health Canada for its Symplicity Spyral™ multi-electrode Renal Denervation (RDN) System. This is indicated for the management of essential...
-
Oct 28, 2022
World Stroke Congress 2022: DiVERT Stroke Study shows significant differences in post-stroke workflow protocols and cardiac monitoring
-
Apr 28, 2022
Heart Rhythm 2022: Sub-analysis indicates patients with intermittent monitoring may not be optimally managed for secondary stroke prevention
-
Apr 12, 2022
AccuRhythm AI algorithms shown to reduce false alerts by 84%